NSCALE/KONTENA
22.7.2024 03:45:01 CEST | Business Wire | Press release
Nscale, a fully vertically integrated AI cloud platform, today announced the acquisition of Kontena, a leader in high-density modular data centres and AI Data Centre solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240721172829/en/
Joshua Payne, Founder and CEO, Nscale (Photo: Business Wire)
This acquisition marks a significant step forward in Nscale's mission to provide the infrastructure backbone to the growing generative AI market through cost-effective, high-performance solutions that unlock AI's full potential.
Jef Laurijssen, CEO of Kontena, commented: “Joining forces with Nscale provides us with an incredible opportunity to accelerate the development and deployment of cutting-edge Generative AI Data Centre solutions. Our combined expertise will enable us to deliver unparalleled value to our customers in the AI and HPC markets.”
Capitalising on Kontena’s innovative KONNECT ecosystem combined with Nscale’s extensive infrastructure capabilities, the two companies will deliver high-performance solutions. Kontena's flagship product, the EDGE data room, is a fully modular Generative AI Data Centre solution designed to meet the complex demands of advancing AI development. The EDGE data room is one of the world’s first modular solution deploying AI infrastructure on-premises and in remote locations, far quicker and at lower cost than traditional Tier 3 Data Centres.
Nscale’s acquisition of Kontena bolsters its commitment to sustainability. Kontena’s modular AI data centre solutions will enable Nscale to deliver faster and more cost-effective deployments for customers at its 100% renewable data centre sites in Norway and the US.
Joshua Payne, CEO of Nscale, commented: “The acquisition of Kontena allows Nscale to design, build, and deploy bespoke GPU clusters at scale for global Generative AI customers more quickly and more cost-effectively than the competition. Building Kontena into the Nscale value chain will allow us to deliver bespoke GPU superclusters and data centre builds for our large supercluster and hyperscale customers across Nscale’s 500MW of greenfield data centre capacity. This modular system can be deployed in Nscale’s data centres, on-premise, or at the edge to deliver unrivalled speed, performance, and efficiency on GenAI workloads. This is an important step towards our goal of vertical integration.”
This acquisition underscores Nscale’s dedication to driving innovation and delivering exceptional value to its customers. It follows Nscale’s recent announcement of a strategic partnership with Open Innovation AI, a leading GPU orchestration platform in MENA, targeting the deployment of 30,000 GPUs over the next 3 years, further solidifying its commitment to AI infrastructure and optimised workloads for global markets.
About Nscale
Nscale is a fully vertically integrated AI GPU Cloud provider delivering compute to the generative AI market at scale. Leveraging its 60MW renewable energy-powered data centre in Norway and a pipeline of over 500MW of greenfield data centres in the US. Nscale enables customers to run efficient and scalable AI training, fine-tuning, and compute-intensive workloads, supporting advanced AI research and development. Nscale provides the AI infrastructure backbone to the generative AI market.
About Kontena
Founded in 2018, Kontena specialises in high-density data centres and HPC solutions, combining innovation with practicality. The company recently collaborated with ElioVP and Bluesio to develop better and more innovative AI and HPC solutions.
For more information about Nscale’s AI & HPC solutions and the Kontena acquisition, visit nscale.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240721172829/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom